Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Bladder Cancer
•
Medical Oncology
How do you manage dysgeusia from Enfortumab Vedotin?
Related Questions
How would you approach adjuvant therapy in MIBC with predominantly squamous cell differentiation?
How do you manage enfortumab vedotin related DKA that is refractory to standard therapy (insulin, fluids, etc)?
What are your top takeaways from ASCO GU 2025?
In patients with muscle-invasive bladder cancer seeking bladder preservation, would positive ctDNA affect your approach to trimodality therapy?
What are your top takeaways in GU Cancers from ESMO 2024?
In patients with localized small cell bladder cancer, would you consider consolidation with durvalumab after neoadjuvant chemotherapy followed by definitive local therapy (cystectomy or RT)?
Would you recommend patients with newly diagnosed bladder cancer to discontinue SGLT2 inhibitors?
How do you decide between internal versus external decompression of malignant obstruction of the ureter (MUO)?
Are there scenarios where you would still prefer adjuvant nivolumab based on known pathologic risk over using perioperative durvalumab for all patients with muscle invasive bladder cancer?
Are you dose reducing/omitting IV dexamethasone as a pre-medication for anti-emesis in patients with MIBC when using durvalumab/gemcitabine/cisplatin?
